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For decades low doses of antibiotics have been widely used in animal production to promote 
growth. However, there is a trend to reduce this use of antibiotics in feedstuffs and legislation 
is now in place in Europe to prohibit their use in this way. As a consequence economically 
important diseases, such as necrotic enteritis (NE) of chickens, caused by Clostridium 
perfringens, have become more prevalent. Recent research is creating a paradigm shift in our 
understanding of the pathogenesis of NE and is now providing information that will be 




Removing antimicrobial growth promoters and the rise of necrotic enteritis  
For decades antibiotics have been extensively used in animal production worldwide1 (see text 
box 1). Added in low doses to the feed of farm animals, they have been shown to increase 
daily weight gain and conversion of feed into body mass, leading to economic advantages for 
farmers2,3,4,5. However, there is an increasing trend to reduce this use of antibiotics in 
feedstuffs. There are concerns that the use of antibiotics in the feed contributes to the spread 
of antibiotic resistance genes by promoting the selection of antibiotic resistant bacteria in 
animals. Also, waste materials from animals may contain antibiotic residues, resulting in their 
wider dissemination in the environment.  Since January 1st 2006, legislation has been in place 
in Europe to prohibit the use of antibiotics as growth promoters and in other continents the 
use of antimicrobial growth promoters in feedstuffs is under debate6,7,8. 
 
The reduction in use of antibiotic growth promoters has had both expected and unexpected 
effects. The absence of antibiotic growth promoters is known to result in reduced feed 
conversion efficiencies9; this has had economic consequences for livestock producers but is a 
manageable problem. More worryingly, some animal diseases have become more 
widespread – there are emerging diseases arising as a consequence of changes in farming 
practices. One of the most significant emerging diseases is necrotic enteritis (NE) of broiler 
chickens, which is caused by Clostridium perfringens. The full impact of the reduction in 
antibiotic growth promoters on the incidence of NE is not yet known because many countries 
are still implementing policies to reduce antibiotic usage in feedstuffs. However, insight into 
the extent of the problem can be gained from analyzing data from countries that had 
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abolished antibiotic growth promoters prior to the EU legislation. In Scandinavia the banning 
of antibiotic growth promoters was accompanied by a dramatic increase in the incidence of 
NE in poultry. For example, in Norway, most of the feed companies abolished antibacterial 
growth promoters in 1995 and within one month increases in the incidence of NE in flocks 
were evident, indicating that the AGPs had been an effective prophylactic treatment 
controlling NE. The problem was so great that alternative prescription antibiotics were 
introduced, although the total quantities of antibiotics used to treat NE were less than those 
used in feed10,11. AGPs continue to be used in many of the major poultry producing regions, 
including North and South America and Asia. It has been estimated that NE costs the 
international poultry industry about 2 billion US dollars annually12,13.  The latest research into 
the biology of NE is precipitating a reassessment of our understanding of the disease process 
and is offering new avenues for the development of vaccines to address this important 
economic issue. 
 
Necrotic enteritis in broiler chickens 
C. perfringens produces several myonecrotic and gastrointestinal diseases in humans, 
domesticated livestock and in birds14,15. As a species C. perfringens is capable of producing a 
wide range of toxins (see Text box 2), but individual strains produce only a sub-set of these 
toxins. The differential production of the four so-called major toxins (α-, β-, ε- and ι-toxin) is 
used to classify strains into five toxinotypes (A, B, C, D and E)16. In poultry, both clinical and 
subclinical NE are typically caused by C. perfringens type A17. Of the major typing toxins, type 
A strains produce only α-toxin, which is responsible for the ability of C. perfringens strains to 
cause gas gangrene18. 
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Since spores of C. perfringens type A are ubiquitous in the environment and are ingested 
continuously via poultry feed, it is generally accepted that predisposing factors are required 
for these bacteria to cause disease. Complex interactions between members of the gut flora 
play a role in establishing NE. The best known predisposing factor is pre-existing mucosal 
damage caused by coccidiosis19,20,21. Coccidiosis is caused by Eimeria parasites that colonize 
the gut and kill epithelial cells as a consequence of the intracellular stages of their life cycle. 
The resulting gaps in the epithelial lining of the intestinal lumen may trigger rapid replication 
and/or toxin production by certain C. perfringens strains.  
 
Necrotic enteritis is characterised clinically by a sudden increase in flock mortality, often 
without premonitory signs although wet litter is sometimes an early indicator of disease. At 
necropsy large necrotic foci are found in the small intestinal mucosa (Fig 1a) and in severe 
cases the whole mucosal surface of the gut is affected, with extensive necrosis of the lumen 
surface (Fig 1b). The typical form of the disease leads to increased mortality in broiler flocks 
during the last weeks of the rearing period20. In the past few years, for reasons that are not 
clear, C. perfringens has been associated with a form of NE with clinical signs that are milder 
than the classical acute form of NE22,23,24.  In this subclinical form, C. perfringens causes 
chronic damage to the intestinal mucosa, which leads to decreased digestion and absorption, 
reduced weight gain and increased feed conversion ratio25,26 It is this manifestation of the 





Histopathology of NE lesions 
Early microscopic studies of NE lesions described clearly demarcated foci of advanced tissue 
degeneration with villi partially or fully denuded of epithelium, large sheets of disintegrating 
cells found in the lumen and congestion of blood vessels in the lamina propria and 
submucosa28,29. Recent studies of earlier stages of disease have provided valuable new 
insights into the pathogenesis of NE, indicating damage to the villi initially occurs in the 
basement membrane and lateral domain of the enterocytes, spreading throughout the lamina 
propria. Epithelial damage occurs later in the process30. Olkowski et al. (2008)30 concluded 
that the morphological changes indicated that the initiation of pathology involves factors 
affecting the extracellular matrix and cellular junctions. It was suggested that the pathology 
may be the result of bacterial collagenases, whose action is enhanced when mucosal 
damage (e.g. induced by coccidia) is present, or host matrix metalloproteinases that are 
activated by the host-pathogen interaction30. It is interesting to note that one of the recently 
identified, potentially protective, vaccine antigens from C. perfringens may be a zinc 
metallopeptidase31. 
 
Do Clostridium perfringens toxins play a role in NE? 
For more than 20 years, α-toxin has been proposed to be the main virulence factor for NE in 
poultry. The origin of this assumption is unclear, but seems to lie in the observations that 
crude supernatant from C. perfringens type A cultures induced necrotic lesions in broilers32 
and that serum containing antibodies to C. perfringens α-toxin prevented the development of 
lesions33. Maternal vaccination with a crude C. perfringens type A and C toxoid has been 
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shown to induce antibodies against α-toxin in chicks, which were partially protected against 
NE34. The interpretation of these early studies is unclear because they used crude 
supernatant and the assumption was made that the effects were caused by the dominant 
protein present, i.e. α-toxin. However, many other proteins are also present in the supernatant 
of C. perfringens cultures. More recently, other epidemiological and experimental evidence 
has supported the proposal that α-toxin is an important protective antigen. Two independent 
studies have shown that poultry that are immune to NE have high titres of antibodies to α-
toxin35,36.  Recently, more convincing evidence of the possible involvement of α-toxin has 
come from immunization with purified α-toxoid, which induced protection against 
experimentally induced NE31.   
 
Against this background, other recent studies have clearly indicated that α-toxin plays no 
direct role in the pathogenesis of NE.  C. perfringens isolates associated with NE and isolates 
derived from the microbiota of normal broilers are predominantly type A37. There is no 
apparent difference in the levels of α-toxin production in vitro by normal microbiota and 
outbreak isolates38. In fowl models of NE the disease can be reproduced by type A strains 
from outbreaks of NE but not by other type A strains, even though both groups of isolates 
produce α-toxin39. However, the most convincing evidence of the lack of involvement of α-
toxin in disease comes from studies using an α-toxin negative mutant of a C. perfringens 
strain from an NE outbreak. In virulence trials both the wild-type strain and an isogenic α-toxin 
negative mutant were able to cause NE lesions in chickens39.  In contrast, in another study 
spontaneously derived α-toxin mutants of a virulent strain clearly had an impaired ability to 
cause NE lesions40. However, these mutants were not complemented with a functional α-toxin 
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gene so it was not clear that the reduced virulence was due to the impairment of α-toxin 
production. 
 
Other observations also argue strongly against a role for α-toxin in NE. The massive 
inflammation caused by granulocytes transmigrating from the tissue into the lumen is a 
hallmark of broiler NE38,41.  It is markedly different to the leukostasis and lack of inflammation 
induced by α-toxin in gas gangrene42. Indeed, α-toxin negative mutants of C. perfringens do 
promote profound inflammatory responses and are unable to cause gas gangrene in mice18. 
Thus the massive immune cell influx in NE lesions seems to be inconsistent with the known 
effects of α-toxin on the innate immune system38,41. Further, histological analysis of tissue 
damage occurring in early stages of lesion development is not consistent with the 
phospholipase C or sphingomyelinase activities of α-toxin30. 
 
With evidence mounting that α-toxin did not play a major role in the pathogenesis of NE there 
was a need to reevaluate previous work and an opportunity to search for other factors 
important in pathogenesis. The earlier evidence used to suggest a role for α-toxin is still 
valuable because it did indicate that there are molecules in C. perfringens culture supernatant 
that when infused into gut reproduced disease-like pathology32. This result showed that 
significant virulence factors must be present in the secreted cell products. 
 
NetB, the new toxin on the block 
Recently, NetB, a novel toxin that is associated with broiler NE has been described43. The 
toxin was identified using screens for proteins from the supernatant of C. perfringens cultures 
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that were cytotoxic for chicken hepatocellular carcinoma cells (LMH) in vitro. The netB 
structural gene was identified by genomic sequencing of an NE isolate43.  Both native and 
recombinant NetB were shown to be cytotoxic for LMH cells and the mechanism of action 
appears to involve the formation of small hydrophilic 1.6 -1.8 nm pores43. A netB mutant of C. 
perfringens was unable to cause necrotic lesions in the gut of experimentally infected broilers, 
but a complemented netB mutant was virulent, like the wild-type strain43. Additional evidence 
for the role of NetB in disease comes from the finding that most NE outbreak strains carry the 
netB gene, whilst C. perfringens isolates from other diseases of animals lack this gene and 
therefore do not produce NetB toxin. This finding has been confirmed and extended by the 
authors of this review for isolates from Denmark and Belgium, where eight out of eleven 
isolates from diseased chickens carried the netB gene, compared to one out of thirty-two 
isolates from healthy broilers. However, this story may yet have some further twists to the tail. 
It is unclear whether the occasional NE isolates that lack the netB gene posses a sequence 
divergent from that of the published toxin or whether other as yet unidentified toxins can 
confer disease-causing potential on C. perfringens isolates. A further complication is that not 
all strains isolated from diseased birds are necessarily still pathogenic, for instance 
Thompson et al. (2006) 40 found that two of the six isolates they tested were not pathogenic. 
Hence, caution is required when interpreting surveys of isolates from disease outbreaks; 
isolates may change during the culturing process or there may even be a mixture of 
pathogenic and non-pathogenic stains present in some diseased birds. 
 
It is possible that other virulence factors, such as hydrolytic enzymes and other (unidentified) 
toxins also play a role in the complex pathogenesis of the disease. For example, it has been 
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suggested that in the initial stages of NE proteolytic enzymes play an important role, causing 
disruption of the basal lamina matrix and the lateral domain of enterocytes30. Indeed, in 
broilers undergoing NE, the extracellular matrix is disorganized and can even be completely 
absent.  
 
Vaccination with α-toxin 
Until recently, most vaccination efforts directed against NE have concentrated on the use of 
culture supernatant toxoids in which α-toxin was the major component34,44,45. These trials 
have been of limited success. More recently, vaccines using recombinant α-toxin and live 
delivery of α-toxin by attenuated Salmonella have been evaluated and shown to give partial 
protection against NE in experimental challenge models31,46,47. With evidence accumulating 
that α-toxin may not play an important role in NE pathogenesis the question arises as to how 
antibodies to the protein can offer any level of protection. α-toxin is the major protein found in 
C. perfringens culture supernatants and so it was always regarded solely as a secreted 
protein. As such it was difficult to see how antibodies to the protein could affect disease 
outcomes if α-toxin was not an important factor in pathogenesis. 
 
Insight into the role in protection of antibodies to α-toxin comes from a recent study by 
Zekerias et al. (2008)47. These researchers found that serum from broilers that had been 
vaccinated with a Salmonella enterica subspecies Typhimurium ∆asd pabA pabB mutant 
secreting the C-terminal (non-toxic) domain of α-toxin bound to the cell surface of C. 
perfringens and suppressed its growth in broth cultures. This result clearly shows that 
although α-toxin is primarily secreted some toxin must also be retained on the cell surface. 
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Antibody binding may have subsequently blocked some C. perfringens cellular process or 
interaction with the host47. There are important parallels here with findings from other bacteria 
species, where antibodies to ABC transporter proteins, which are not virulence factors, can 
provide protection against disease, possibly by interfering with the transport of materials into 
or out of the cell48. It is clear that α-toxoid can be used as a protective antigen to vaccinate 
broilers, but this does not automatically indicate a primary role in the pathogenesis of the 
disease. 
 
Identification of other vaccine antigens 
Thompson et al. (2006) 40 have used attenuated strains of C. perfringens that no longer 
express α-toxin to vaccinate chickens. They found that the attenuated vaccine strains offered 
varying levels of protection. This study clearly demonstrated that C. perfringens carries other 
molecules that can provide some efficacy as vaccine antigens. Subsequent work by this 
group has identified several immunoreactive proteins in virulent C. perfringens strains that, in 
recombinant subunit form, offer some protection when used as vaccines31. Two of these 
proteins, fructose-biphosphate-aldolase, and a hypothetical protein (possibly a 
metallopeptidase) also gave some protection when delivered by a live Salmonella vector48. 
Other proteins that have been shown to play a role in pathogenesis will be well worth testing 
as vaccine antigens. These include the NetB protein identified by Keyburn et al. (2008)43 and 






The story of NE in intensively reared poultry is fascinating and highlights some of the pitfalls 
in both policy and in research. The abolition of growth promoters in feedstuffs was initially 
accompanied by significant increases in disease in animals. In part, this change in the pattern 
of disease reflects the ways in which farming practices have become interdependent and the 
difficulties associated with isolated changes in these practices. The story of NE also highlights 
the dangers of making scientific assumptions and the ease with which such assumptions can 
become embedded in the literature as fact. However, the story is not one only of pitfalls and 
problems. The research carried out over the past few years is creating a paradigm shift in our 
understanding of the pathogenesis of this disease and is now providing the essential 
information that will be required to monitor and control the incidence of NE in poultry. As new 
tools, such as relatively cheap whole genome sequencing, targeted mutation and improved 
disease models are developed we are better able to investigate issues such as the complex 
etiology of this multifactorial disease. We can look forward to major advances in our 
understanding of the impact of various genetic and environmental changes on the host-
pathogen interaction and how this affects the incidence and severity of disease. Deeper 
understanding of these issues should facilitate the development of effective disease control 
measures. 
 
TEXT BOX 1. What are antimicrobial growth promoters ? 
Antimicrobial growth promoters are substances that are added to the feed in sub-
therapeutic levels in intensive animal rearing (poultry, pigs, cattle) to improve weight 
gain and conversion of feed into body mass7,50. Reduced mortality and morbidity due 
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to subclinical and clinical disease is also achieved7,50. The mechanism of action of 
antimicrobial growth promoters is unknown, but most likely their action is mediated by 
their antibacterial effects7. It is believed that there is increased nutrient availability to 
the host when the number of gut bacteria is decreased51. Furthermore, the production 
of toxins by gut bacteria is diminished with consequent beneficial effects on the gut 
wall integrity51. Concerns over the development of bacterial antibiotic resistance and 
thus the impairment of the efficacy of therapeutic drugs for humans have led to 
recommendations on the reduction and elimination of the use of antimicrobial growth 
promoters as animal feed supplements8,52. In the EU, the use of antimicrobial growth 
promoters in animal feed has been banned since 1st January 20066. However, although 
antibiotics have been withdrawn, coccidiostats are still in use and these agents also 
have some antimicrobial activity6. In the US, there is little regulatory activity regarding 
the use of these substances, but consumer concerns are influencing debates on the 
use of antimicrobial growth promoters.   
 
TEXT BOX 2; Clostridium perfringens toxins 
C. perfringens is able to cause a wide range of diseases in humans and animals, 
ranging from food poisoning to severe invasive disease15,53,54. The ability of C. 
perfringens to cause disease is ascribed mainly to the differential production of four 
major and 10 minor protein toxins15,55. The roles of some of these toxins in disease is 
well understood. For example, α-toxin, which is produced by all five toxinotypes, is the 
main virulence determinant in gas gangrene and mutated strains that are unable to 
produce α-toxin are unable to cause disease in mice18,54. The ε- and β-toxins appear to 
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play key roles in enterotoxaemia in calves, lambs, piglets and goats and most of the 
domesticated livestock in developed countries are immunised against disease with 
toxoid vaccines. The C. perfringens enterotoxin, CPE, is a major cause of human food 
poisoning in the USA and Europe53,56,57. The roles of the other toxins are less well 
understood, indeed some may not play a role in disease. The most recently discovered 
toxins are the beta-2 toxin and NetB toxin. The beta-2 toxin has not been shown 
conclusively to play a role in disease, but NetB toxin is now known to play a major role 
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Fig. 1. Typical gut lesions in severe broiler necrotic enteritis, (a) consisting of patches of 
necrosis throughout the gastrointestinal tract and in extreme cases (b) extensive necrosis of 
the mucosal surface. 
 
 
 
 
